Shares of Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO – Get Free Report) have been assigned a consensus rating of “Hold” from the eight brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $3.25.
Several analysts have issued reports on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Mereo BioPharma Group in a research note on Monday, March 23rd. Zacks Research upgraded Mereo BioPharma Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mereo BioPharma Group in a report on Thursday, July 2nd. Lifesci Capital raised Mereo BioPharma Group to a “hold” rating in a research report on Thursday, March 19th. Finally, BTIG Research restated a “buy” rating and set a $1.00 price objective on shares of Mereo BioPharma Group in a research note on Tuesday, May 12th.
Check Out Our Latest Stock Analysis on Mereo BioPharma Group
Institutional Trading of Mereo BioPharma Group
Mereo BioPharma Group Trading Up 3.3%
MREO stock traded up $0.01 during mid-day trading on Friday, hitting $0.34. 1,356,077 shares of the company were exchanged, compared to its average volume of 1,501,099. The firm has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.43. The company has a market capitalization of $53.47 million, a PE ratio of -6.70 and a beta of 0.35. Mereo BioPharma Group has a twelve month low of $0.20 and a twelve month high of $2.37.
Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). As a group, sell-side analysts anticipate that Mereo BioPharma Group will post -0.02 earnings per share for the current year.
Mereo BioPharma Group Company Profile
Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.
Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.
Featured Articles
- Five stocks we like better than Mereo BioPharma Group
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.
